B43-PAP IMMUNOTOXIN COMBINED WITH STANDARD 4 DRUG INDUCTION FOR CD+ ALL

B43-PAP 免疫毒素与标准 4 药物诱导相结合治疗 CD ALL

• 批准号: 6274718
• 负责人: RAYMOND J HUTCHINSON
• 金额: $ 2.15万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274718
• 关键词: CD antigens; acute lymphocytic leukemia; antineoplastics; asparaginase; child (0-11); clinical research; clinical trials; combination cancer therapy; drug screening /evaluation; human subject; human therapy evaluation; immunoconjugates; immunotoxicity; monoclonal antibody; neoplasm /cancer chemotherapy; pediatric neoplasm /cancer; pediatric pharmacology; prednisone

CCG 0957 is a phase-I study to determine the toxicity of B43-PAP when given concurrently with a standard four drug re-induction (Vincristine, Prednisone, L'Asparaginase, Daunomycin) in pediatric patients with acute lymphoblastic leukemia (ALL). B43-PAP is an immunotoxin (monoclonal antibody-toxin conjugate) which has been studied for the past 9 years by Dr. Fatih Uckun at the Children's Cancer Group Immunotoxin Resource Laboratory in Minneapolis. Single institution studies have been done at the University of Minnesota. B43 is the monoclonal antibody selected for the protocol because it is targeted toward the CD19 antigen, which displays specificity for pre-B lineage ALL - the most common type of leukemia in children.

CCG 0957是一项i期研究，旨在确定B43-PAP的毒性